The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Schizophrenia

Treatments: Drug: AZD8529; Drug: Placebo to match AZD8529

Study type: Interventional

Funder types: Industry

Identifiers

NCT00986531

D2285M00016

Details and patient eligibility

About

The purpose of this study is to assess if AZD8529 improves performance on neurobehavioral probes of attention, working memory and affective reactivity in patients with schizophrenia.

Enrollment: 59 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• DSM-IV diagnosis of schizophrenia or schizoaffective disorder

Exclusion criteria

• ECT in the last 6 months
• Substance abuse or dependence
• History of claustrophobia

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

59 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

80 mg AZD8529

Treatment:

Drug: AZD8529

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo to match AZD8529